clinical trial · NCT04941001
Optimisation of ASthma In Those With Uncontrolled Symptoms (OASIS)
AsthmaAsthma AttackAsthma PersistentCovid19ReferID
brief summary
A digital tool, called ReferID has been developed to facilitate the review of asthma patients. It aims to assist in the identification of patients with uncontrolled and/or severe asthma and to ensure a timely referral to secondary care where appropriate. To validate the tool, patients will be randomised to have a review with a healthcare professional using tool to facilitate the review or to continue receiving usual care. Outcome measures including exacerbation frequency and level of asthma control will be assessed at 12 months.
started
Aug 9, 2021
primary completion
Feb 1, 2023
completion
Feb 1, 2023
last updated
Aug 28, 2023
official title
Optimisation of ASthma In Those With Uncontrolled Symptoms (OASIS) in Primary Care Using a Digital Consultation Tool During the COVID-19 Pandemic
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol